Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations

BACKGROUND: Selective tyrosine kinase inhibitors targeting fibroblast growth factor receptor (FGFR) 1-4 genomic alterations are in development or have been approved for FGFR-altered cancers (e.g. bladder cancer and advanced intrahepatic cholangiocarcinoma). Understanding FGFR inhibitor-resistance me...

Descripción completa

Detalles Bibliográficos
Autores principales: Murugesan, K., Necchi, A., Burn, T.C., Gjoerup, O., Greenstein, R., Krook, M., López, J.A., Montesion, M., Nimeiri, H., Parikh, A.R., Roychowdhury, S., Schwemmers, S., Silverman, I.M., Vogel, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832751/
https://www.ncbi.nlm.nih.gov/pubmed/36462464
http://dx.doi.org/10.1016/j.esmoop.2022.100641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832751/
https://www.ncbi.nlm.nih.gov/pubmed/36462464
http://dx.doi.org/10.1016/j.esmoop.2022.100641

Ejemplares similares